Super Patient: Chris Newman Seeks a Second Opinion—and Survives Lung Cancer


In late 2009, Chris Newman thought she was just another busy person who kept feeling run down. “I had profound fatigue for a year and two bouts of bronchitis,” recalls Chris, who was a lawyer at the time.

Then a bad case of pneumonia took her to the emergency room, where an X-ray revealed a large mass—nearly three inches across—and several small ones in her lungs. A biopsy showed she had non-small cell lung cancer, a PET scan for sugar uptake showed it was extremely aggressive, and genetic testing showed there was no targeted treatment for it. Continue reading…


How A Group Of Lung Cancer Survivors Got Doctors To Listen

“A group of lung cancer survivors was chatting online last May about what they thought was a big problem: Influential treatment guidelines published by a consortium of prominent cancer centers didn’t reflect an option that several people thought had saved their lives. They wanted to change that.

“The guidelines from the National Comprehensive Cancer Network are important because they’re often a first stop for an oncologist trying to develop a treatment plan after a patient’s diagnosis, Chris Newman, one of the patient group’s members, told Shots. But the guidelines don’t always reflect newer and less proven treatment options that may be offered only at big academic cancer centers, she said. Patients might miss out on treatments that could help them, if the guidelines aren’t up to date.

“That’s what Newman and others thought was happening for some patients with a type of advanced non-small cell lung cancer. When cancer has spread, or metastasized, beyond the original site, it’s diagnosed as stage IV. And it’s historically been a pretty black and white diagnosis. With most forms of cancer, you have metastases or you don’t, says Paul Okunieff, a radiation oncologist and director of the University of Florida Health Cancer Center. Patients whose cancer has spread are often offered chemotherapy or supportive care rather than surgery or radiation to remove the tumors, on the assumption that it’s too late to prevent further spread.

“But some research suggests that patients with oligometastases, or a limited number of tumors (Okunieff says it’s fewer than three or five, depending on whom you ask) may get significant benefit from more aggressive treatment. That possibility wasn’t reflected in the NCCN guidelines.”